MedPath

Efficacy of Repeated courses of Rituximab vs. Rituximab and Mycophenolate Mofetil among Children Nephrotic Syndrome

Phase 3
Conditions
Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality
Registration Number
CTRI/2019/04/018517
Lead Sponsor
RS Medical college and Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Children between 3 and 16 years with SDNS.

2.Minimal Change disease/ FSGS/MesPGN as per Kidney Biopsy report.

3.Estimated glomerular filtration rate(eGFR) >80 ml/min per 1.73 m2 at study entry.

4.Remission at study entry (Urine albumin nil or trace (or proteinuria <4 mg/m2/h) for 3 consecutive early morning specimens).

5.Not received any steroid sparing agent previously.

6.Parents willing to give informed written and audiovisual consent.

7.Ability to swallow tablet.

Exclusion Criteria

1.Known etiology (e.g., lupus erythematosus, IgA nephropathy, amyloidosis, malig-nancy, other secondary forms of NS).

2.Patients with severe leukopenia (leukocytes <3.0Ã? 1000 cells/mm3), severe anemia (haemoglobin <8.9 g/dl), thrombocytopenia (platelet <100.0 Ã? 1000 cells/mm3) orderanged liver function tests (AST or ALT to >50 IU/L ) at enrolment.

3.Known active chronic infection (tuberculosis, HIV, hepatitis B or C).

4.Live vaccination within one month prior to screening.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is the time to first relapse or death (whichever occurs first) till end of study (follow-up phase of 24 months).Timepoint: The primary endpoint is the time to first relapse or death (whichever occurs first) till end of study (follow-up phase of 24 months).
Secondary Outcome Measures
NameTimeMethod
1.Cumulative prednisolone requirement (mg/kg/yr) over the first 12 and 24 months, respectively. <br/ ><br>Timepoint: 12 and 24 months;Number and severity of adverse eventsTimepoint: 0-24 months;Number of relapses within months 0-24, 0-12 and 12-24, respectivelyTimepoint: months 0-24, 0-12 and 12-24
© Copyright 2025. All Rights Reserved by MedPath